Please use this identifier to cite or link to this item:
|Title:||Outcomes of endovascular thrombectomy with and without bridging thrombolysis for acute large vessel occlusion ischaemic stroke.|
|Authors:||Maingard, Julian;Shvarts, Yasmin;Motyer, Ronan;Thijs, Vincent N;Brennan, Paul;O'Hare, Alan;Looby, Seamus;Thornton, John;Hirsch, Joshua A;Barras, Christen D;Chandra, Ronil V;Brooks, Duncan Mark;Asadi, Hamed;Kok, Hong K|
|Affiliation:||Monash University, Melbourne, Victoria, Australia|
Neuroendovascular Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Interventional Neuroradiology Unit, Monash Imaging, Monash Health, Melbourne, Victoria, Australia
Department of Imaging, Monash University, Melbourne, Victoria, Australia
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Interventional Radiology, Department of Radiology, Northern Hospital, Melbourne, Victoria, Australia
Interventional Neuroradiology Service, Department of Radiology, Austin Health, Heidelberg, Victoria, Australia
School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia
Stroke Division, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
Interventional Neuroradiology Service, Department of Radiology, Beaumont Hospital, Dublin, Ireland..
|Citation:||Internal Medicine Journal 2019-03; 49(3): 345-351|
|Abstract:||Endovascular thrombectomy (EVT) for management of large vessel occlusion (LVO) acute ischaemic stroke is now current best practice. To determine if bridging intravenous (i.v.) alteplase therapy confers any clinical benefit. A retrospective study of patients treated with EVT for LVO was performed. Outcomes were compared between patients receiving thrombolysis and EVT with EVT alone. Primary end-points were reperfusion rate, 90-day functional outcome and mortality using the modified Rankin Scale (mRS) and symptomatic intracranial haemorrhage (sICH). A total of 355 patients who underwent EVT was included: 210 with thrombolysis (59%) and 145 without (41%). The reperfusion rate was higher in the group receiving i.v. tissue plasminogen activator (tPA) (unadjusted odds ratio (OR) 2.2, 95% confidence interval (CI): 1.29-3.73, P = 0.004), although this effect was attenuated when all variables were considered (adjusted OR (AOR) 1.22, 95% CI: 0.60-2.5, P = 0.580). The percentage achieving functional independence (mRS 0-2) at 90 days was higher in patients who received bridging i.v. tPA (AOR 2.17, 95% CI: 1.06-4.44, P = 0.033). There was no significant difference in major complications, including sICH (AOR 1.4, 95% CI: 0.51-3.83, P = 0.512). There was lower 90-day mortality in the bridging i.v. tPA group (AOR 0.79, 95% CI: 0.36-1.74, P = 0.551). Fewer thrombectomy passes (2 versus 3, P = 0.012) were required to achieve successful reperfusion in the i.v. tPA group. Successful reperfusion (modified thrombolysis in cerebral infarction ≥2b) was the strongest predictor for 90-day functional independence (AOR 10.4, 95% CI:3.6-29.7, P < 0.001). Our study supports the current practice of administering i.v. alteplase before endovascular therapy.|
large vessel occlusion
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.